This RARE-NL meeting on 11 March at LUMC focuses on the development and implementation of antisense oligonucleotides for n-of-few and n-of-1 indications. The meeting brings together researchers, clinicians and experts in access pathways to explore how ASOs can be translated into clinical practice. The emphasis is on shared challenges and solutions that require collaboration beyond individual UMCs.

Please register via this link.

The hDMT/RARE-NL preclinical network meeting will take place in the morning of the same day. For more information see this page.